Cellectar raises ~$5.8M via warrant exercise; prelim cash $12.6M as of Sep 30

Cellectar Biosciences, Inc.

Gross proceeds of ~$5.8M from exercise of 1,048,094 existing warrants at $5.25/share; holders paid $0.125 per new warrant.
Preliminary cash and equivalents ~$12.6M as of Sep 30, 2025; combined with net proceeds of ~$5.2M, runway extends into Q3 2026.
Issued Series I warrants (exercisable at $6.00, 5-yr term) and Series II warrants (exercisable at $6.00, 18-mo term) for 100% of exercised shares.
Company to file a resale registration statement for new warrant shares within 15 days of closing.

item 1.01item 2.02item 3.02item 3.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.